These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 9349695)
1. Patient participation and compliance in cancer chemoprevention trials: issues and concerns. Tangrea JA Proc Soc Exp Biol Med; 1997 Nov; 216(2):260-5. PubMed ID: 9349695 [TBL] [Abstract][Full Text] [Related]
2. Participant enrollment, participation, and compliance in chemoprevention trials. Rimer BK Adv Exp Med Biol; 1992; 320():111-7. PubMed ID: 1442275 [TBL] [Abstract][Full Text] [Related]
3. Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial. Hudmon KS; Love RR; Chamberlain RM J Cancer Educ; 1999; 14(2):83-7. PubMed ID: 10397482 [TBL] [Abstract][Full Text] [Related]
4. [Chemoprevention of cancers]. Espie M Bull Cancer; 1995 Jul; 82 Suppl 3():181s-185s. PubMed ID: 7492832 [TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. Greenwald P J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595 [TBL] [Abstract][Full Text] [Related]
7. The clinical evaluation of cancer prevention agents. Goodman GE Proc Soc Exp Biol Med; 1997 Nov; 216(2):253-9. PubMed ID: 9349694 [TBL] [Abstract][Full Text] [Related]
8. Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment. Battaglia TA; Ash A; Prout MN; Freund KM Cancer Detect Prev; 2006; 30(1):34-7. PubMed ID: 16476525 [TBL] [Abstract][Full Text] [Related]
9. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of cancer. Tsao AS; Kim ES; Hong WK CA Cancer J Clin; 2004; 54(3):150-80. PubMed ID: 15195789 [TBL] [Abstract][Full Text] [Related]
11. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer. Yeomans Kinney A; Vernon SW; Shui W; Weber DV; Schell M; Vogel VG Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):591-5. PubMed ID: 9681527 [TBL] [Abstract][Full Text] [Related]
12. The behavioral dynamics of clinical trials. Leventhal H; Nerenz DR; Leventhal EA; Love RR; Bendena LM Prev Med; 1991 Jan; 20(1):132-46. PubMed ID: 2008422 [TBL] [Abstract][Full Text] [Related]
13. Ethical issues: changing attitudes and practices. Henderson MM Cancer Detect Prev; 1994; 18(4):323-7. PubMed ID: 7982242 [TBL] [Abstract][Full Text] [Related]
14. Risk biomarkers and current strategies for cancer chemoprevention. Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592 [TBL] [Abstract][Full Text] [Related]
15. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Kinney AY; Richards C; Vernon SW; Vogel VG Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803 [TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of human cancer: a reasonable strategy? Meyskens FL Recent Results Cancer Res; 1999; 151():113-21. PubMed ID: 10337722 [TBL] [Abstract][Full Text] [Related]
17. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Moyad MA Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864 [TBL] [Abstract][Full Text] [Related]
18. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Moyad MA Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention clinical trials: it is time to turn success into progress. Brown PH Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123 [No Abstract] [Full Text] [Related]